[ad_1]
The European Union is examining an approved procedure for using a drug called remdesivir to treat patients infected with the coronavirus, writes MTI, citing the Swedish Medicines Agency. Charlotta Bergqvist, an epidemiologist at the Swedish Medicines Licensing Authority, told Swedish television TV4 that a decision on the introduction of remdesivir could be made in a few days.
The United States Food and Drug Administration (FDA) on Saturday approved the use of remdesivir to treat people infected with coronavirus with a particularly serious condition. Earlier this week, Japanese Prime Minister Abe Sindzo also announced that remdesivir is expected to be approved against the virus-induced Covid-19 disease.
related
A week ago, the manufacturer wrote that remdesivir was not effective against Covid-19, but citing a promising study, the FDA still granted approval.
The drug was developed by the American company Gilead Sciences as a possible antidote against Ebola. According to a recent study in the prestigious medical journal The New England Journal of Medicine, the use of remdesivir is approximately 70 percent effective, but can have serious kidney side effects, for example. The drug is currently being tested in many investigations, the first results were not convincing, but more and more countries announce that they will start using the drug to treat the disease.
related
Remdesivir’s failure was first reported by the WHO, but it turned out that a summary report of the experiments was accidentally posted on the organization’s website.
István Vályi-Nagy, Director General of the National Institute of Hematology and Infectious Diseases of the Central Hospital for Southern Plagues, said at a press conference on Saturday that Hungary is one of the first to participate in clinical trials of intravenous remdesivir with Poland. they start at St. Ladislaus Hospital.
records
[ad_2]